Loading…
← CockpitCompetitor Analysis › RGEN Repligen CorporationOpen in the cockpit ↗

Repligen CorporationRGENCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Sells bioprocessing tools and consumables (filtration, chromatography) used to manufacture biologic drugs.

Momentum leader 84
Mkt cap
$11.0B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$221M
20-day average traded
Fwd P/E
71.0×
forward earnings
ROIC−WACC
-7.5 pp
WACC 10.3%
Hurdle
+42 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$172.67
1D+6.5%
1W0.0%
1M-3.5%
3M-4.2%
6M+54.5%
YTD+5.4%
1Y+15.9%
ATR %4.8%
Beta1.21
52w lowhigh13.2% off high

What Repligen does

Sells bioprocessing tools and consumables (filtration, chromatography) used to manufacture biologic drugs.

Sells consumables and equipment that customers reorder every time they make a batch of a drug, so revenue rises when a drug that specifies its parts reaches higher volumes. Growth has come largely through buying other makers of filtration and chromatography components.

Products and services

  • Chromatography resins/systems
  • Filtration (tangential flow, depth)
  • Cell-culture media
  • Process analytics

Customers

  • Biopharma manufacturers
  • Contract manufacturing organizations (CDMOs)

Where it sits in the supply chain

  • Life sciences tools
  • Bioprocessing equipment/consumables
  • Biologics manufacturing supply chain

What could go right

  • Growth in biologics/cell-and-gene-therapy manufacturing demand
  • Share gains in single-use bioprocessing

What could go wrong

  • Biopharma capex cyclicality/destocking
  • Customer concentration among a few large CDMOs/biotechs

Moat: narrow (switching costs, process know-how, customer qualification). Once qualified into a customer's biologics manufacturing process, switching suppliers requires costly re-validation.

Headquarters: Waltham, Massachusetts, United States · Founded: 1981 · Employees: 2,000

Named competitors

Repligen at a glance

Size Repligen (RGEN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $11.0B, the 727th largest of 3,085 United States companies the cockpit tracks. Shares closed at $172.67 on 18 Nov 2026.

Performance Over six months the shares gained 54.5%, against +5.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 13.8% over the last twelve months (peer median +14.5%); the operating margin is 8.6% (peer median 19.6%).

Valuation It trades at 71.0× forward earnings against a peer median of 32.0× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.5 points below its cost of capital (10.3% WACC).

Credit Repligen has 1 bond outstanding ($143M).

Short interest Short interest is 11.0% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026RGEN 152Peer median 106
Six months, rebased to 100: Repligen against the median of its 20 peers (local-currency closes).

Repligen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$806M$738M$634M$632M$802M
Revenue growth—+16%0%-21%—
Gross profit$394M$351M$284M$277M$429M
EBITDA$167M$158M$109M$135M$253M
Net income-$11.8M$48.9M-$25.5M$35.6M$186M
Free cash flow$105M$91.7M$145M$74.9M$38.7M
Capital expenditure$24.6M$25.7M$32.9M$39.0M$133M
Total debt$692M$690M$686M$712M$423M

Quarterly statements and history in the cockpit →

Repligen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+20%MANKIND600436REC1177TGTX300759DRREDDYSYREZYDUSLIFE6990MDGLHLUN-ALAURUSLABSPRAX4151PTGX2607RYTMIPN688506RGEN6-month return →1-month return →
Up and to the right = strong over both horizons. Repligen is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×MANKIND600436RECTGTX6990MDGLPTGXRGENRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Repligen is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%MANKIND600436RECTGTX6990RGENGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Repligen is the large dot.

Repligen competitors and peer comparison

Head to head with its named competitors (RGEN vs DIM.PA vs DHR vs MRK.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Repligen RGEN$11.0B+55%+14%9%71.0×56.9%
Sartorius Stedim Biotech DIM.PA$24.2B+32%+4%19%45.7×33.4%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%

How Repligen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Repligen against its 20 peers (data as of 18 Nov 2026)
MeasureRGENPeer medianRank in peer set
1-month return-3.5%+7.6%5th lowest of 21
6-month return+54.5%+5.0%4th highest of 21
Distance from 52-week high-13.2%-9.7%9th lowest of 21
Revenue growth (TTM)+13.8%+14.5%10th lowest of 20
Operating margin8.6%19.6%6th lowest of 19
Forward P/E71.0×32.0×5th most expensive of 16
Growth the price implies (Req g, 7 yrs)56.9%17.5%most demanding of 14
Growth delivered (Del g)+15.0%+9.3%4th highest of 14
Hurdle (Req g minus delivered)+41.8 pp-11.0 pp2nd most demanding of 14
ROIC minus cost of capital-7.5 pp+1.4 pp5th lowest of 19
EV / EBITDA65.1×18.2×most expensive of 12
Net debt / EBITDA-1.0×0.6×3rd least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a

Repligen bonds and credit

Repligen has 1 bond outstanding with $143M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Repligen's main competitors?
Named competitors: Sartorius Stedim Biotech (DIM.PA), Danaher (Cytiva) (DHR), Merck KGaA (MRK.DE). The cockpit's measured peer set (industry) also includes Mankind Pharma (MANKIND.NS), Zhangzhou Pientzehuang Pharmaceutical (600436.SS), Recordati (REC.MI), Sbp (1177.HK), TG Therapeutics (TGTX), Pharmaron Beijing (300759.SZ).
Is Repligen expensive compared with its peers?
On forward p/e it trades at 71.0× against a peer median of 32.0×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Repligen stock performed?
Over six months to 18 Nov 2026 the shares returned +54.5% against +5.0% for the median peer; over one year +15.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.